In Vitro Development of Erythroid and Megakaryocytic Cells From a UT-7 Subline, UT-7/GM

  • Norio Komatsu
    From the Division of Hematology, the Department of Medicine, Jichi Medical School, Tochigi-ken, Japan, and the Second Department of Pediatrics, Dokkyo Medical School, Tochigi-ken, Japan.
  • Keita Kirito
    From the Division of Hematology, the Department of Medicine, Jichi Medical School, Tochigi-ken, Japan, and the Second Department of Pediatrics, Dokkyo Medical School, Tochigi-ken, Japan.
  • Ritsuko Shimizu
    From the Division of Hematology, the Department of Medicine, Jichi Medical School, Tochigi-ken, Japan, and the Second Department of Pediatrics, Dokkyo Medical School, Tochigi-ken, Japan.
  • Masae Kunitama
    From the Division of Hematology, the Department of Medicine, Jichi Medical School, Tochigi-ken, Japan, and the Second Department of Pediatrics, Dokkyo Medical School, Tochigi-ken, Japan.
  • Minami Yamada
    From the Division of Hematology, the Department of Medicine, Jichi Medical School, Tochigi-ken, Japan, and the Second Department of Pediatrics, Dokkyo Medical School, Tochigi-ken, Japan.
  • Mie Uchida
    From the Division of Hematology, the Department of Medicine, Jichi Medical School, Tochigi-ken, Japan, and the Second Department of Pediatrics, Dokkyo Medical School, Tochigi-ken, Japan.
  • Masaaki Takatoku
    From the Division of Hematology, the Department of Medicine, Jichi Medical School, Tochigi-ken, Japan, and the Second Department of Pediatrics, Dokkyo Medical School, Tochigi-ken, Japan.
  • Mituoki Eguchi
    From the Division of Hematology, the Department of Medicine, Jichi Medical School, Tochigi-ken, Japan, and the Second Department of Pediatrics, Dokkyo Medical School, Tochigi-ken, Japan.
  • Yasusada Miura
    From the Division of Hematology, the Department of Medicine, Jichi Medical School, Tochigi-ken, Japan, and the Second Department of Pediatrics, Dokkyo Medical School, Tochigi-ken, Japan.

抄録

<jats:title>Abstract</jats:title><jats:p>UT-7 is a human megakaryoblastic leukemia cell line with absolute dependence on interleukin-3, granulocyte-macrophage colony-stimulating factor (GM-CSF ), or erythropoietin (EPO) for growth and survival. We isolated a novel subline, UT-7/GM after long-term culture of UT-7 with GM-CSF. The hemoglobin concentration and γ-globin and EPO-receptor mRNA levels were significantly higher in EPO-treated UT-7/GM cells than in untreated cells. In contrast, the platelet factor 4 and glycoprotein IIb mRNA levels were much higher in thrombopoietin (TPO)-treated UT-7/GM cells than in untreated cells. Some TPO-treated cells had morphologically mature megakaryocytic characteristics such as a developed demarcation membrane in the cytoplasm and multilobular nuclei. These findings indicate that UT-7/GM is a bipotential cell line that can be induced to differentiate into erythroid and megakaryocytic lineages by EPO and TPO, respectively. Moreover, a minority of UT-7/GM cells acquired a high hemoglobin concentration by treatment with TPO, suggesting that TPO in part induced the erythroid differentiation of the UT-7/GM cells. Interestingly, GM-CSF inhibited the EPO- or TPO-induced erythroid differentiation and the TPO-induced megakaryocytic differentiation of UT-7/GM cells. These results support the hypothesis that cytokines influence the programming of gene expression required for lineage commitment or differentiation.</jats:p>

収録刊行物

  • Blood

    Blood 89 (11), 4021-4033, 1997-06-01

    American Society of Hematology

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ